WHWK - Whitehawk Therapeutics Inc News

Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Pric

Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK

businesswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Develop

BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whiteha

gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinicall

Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinica

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinicall

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is posit

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Paylo

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, I

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic

seekingalpha.com

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] afte

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "White

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mi

Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by White

Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clin

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinical

MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other em

David James Lennon Sells 26,858 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) CEO David James Lennon sold 26,858 sha

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association fo

MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clin

Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK

Ally Bridge Group NY LLC acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) in the

2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highli

Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16

Contrasting Whitehawk Therapeutics (NASDAQ:WHWK) & Vincerx Pharma (NASDAQ:VINC)

Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) and Vincerx Pharma (NASDAQ: VINC - Get Free

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clini